# NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

> **NCT04880863** · PHASE2 · COMPLETED · sponsor: **NeoTX Therapeutics Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** NAP (Naptumomab estafenatox)
- **DRUG:** Docetaxel
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04880863
- **Lead sponsor:** NeoTX Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-26
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880863, "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04880863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*